IceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025

CAESAREA, Israel, March 21, 2025 /PRNewswire/ — IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure”, “IceCure Medical” or the “Company”), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it will issue a press release with its financial and operational results as of and for the twelve months ended December 31, 2024 before the Nasdaq Stock Market opens on Thursday, March 27, 2025. The Company will also discuss such results and other corporate developments on a conference call at 10:00 a.m. EDT on the same day.

Conference call & webcast info:
Thursday, March 27, 2025, at 10:00 am EDT
US: 1-888-407-2553
Israel/International: +972-3-918-0696
A live webcast will be available at:  https://Veidan.activetrail.biz/IcecureQ4-2024.
A recording of the webcast will be available at: ir.icecure-medical.com/.

About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The Company’s flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe and Asia.

IR Contact: 

Email: [email protected]
Michael Polyviou
Phone: 732-232-6914

Todd Kehrli
Phone: 310-625-4462

Logo – https://mma.prnewswire.com/media/2319310/4496307/IceCure_Medical_Logo.jpg

SOURCE IceCure Medical